Mouse Anti-LOXL2 Recombinant Antibody (HPAB-0160-LSX) (CAT#: HPAB-0160-LSX)

Fan, Zhiyong, et al. "LOXL2 upregulates hypoxia-inducible factor-1α signaling through Snail-FBP1 axis in hepatocellular carcinoma cells." Oncology reports 43.5 (2020): 1641-1649. https://doi.org/10.3892/or.2020.7541

This research investigates the role of Lysyl oxidase-like 2 (LOXL2) in hepatocellular carcinoma (HCC) progression, focusing on its regulatory effect on hypoxia-inducible factor-1α (HIF-1α) signaling. The study demonstrates that LOXL2 inhibits the expression of fructose-1,6-biphosphatase (FBP1) in a Snail-dependent manner, which subsequently enhances glycolysis in HCC cell lines. Importantly, the research reveals that intracellular LOXL2 activity, rather than extracellular LOXL2, is responsible for upregulating HIF-1α/VEGF signaling pathways through the Snail-FBP1 axis. This effect was abolished when using LOXL2 inhibitors, suggesting therapeutic potential.
Creative Biolabs provided an anti-human LOXL2 therapeutic antibody (Simtuzumab; CAT#: HPAB-0160-LSX) that was used to evaluate the binding between the antibody and extracellular LOXL2 protein in immunoprecipitation assays. This antibody helped researchers distinguish between the roles of intracellular and extracellular LOXL2, leading to the critical finding that intracellular LOXL2 activity is primarily responsible for Snail upregulation and subsequent metabolic changes in HCC cells, which represents a significant advancement in understanding potential therapeutic targets for hepatocellular carcinoma.